[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628711":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":53,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MSC therapy","EXPERIMENTAL","200,000,000 cells per infusion",[13],"Drug: MSCs",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline Solution","PLACEBO_COMPARATOR","0.9% saline infusion",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","MSCs","IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","Placebo","Intravenous 0.9% saline infusion, volume- and appearance-matched",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Andrei Peskau, M.D.","CONTACT","+48660639936","info@biocellsmedical.com",[39],{"facility":40,"status":26,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"BioCells Medical","Warsaw","Poland","PL",{"type":45,"coordinates":46},"Point",[47,48],21.01178,52.22977,{"lat":48,"lon":47},[51],{"name":52,"role":35,"phone":36,"phoneExt":26,"email":37},"Miron Danielevich, PhD",{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100628711","phase-2-autologous-stem-cell-therapy-in-patients-with-multiple-system-atrophy-100628711",false,"NCT07465198","Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Multiple System Atrophy (MSA-P or MSA-C)\n* Age range of 35 to 65 years\n\nExclusion Criteria:\n\n* Other major neurological disorders\n* Severe cardiac\u002Frenal\u002Fhepatic impairment\n* Prior stem cell therapy","ALL","35 Years","65 Years",{"count":66,"type":67},50,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo\u002Fcontrolled group.",[73,74],"MSA - Multiple System Atrophy","MSA",[74,76,77,78],"Multiple System Atrophy","MSC","Mesenchimal stem cells","NOT_YET_RECRUITING","2026-03-09",{"date":82,"type":83},"2026-03-11","ACTUAL",{"date":85,"type":67},"2026-09-01",{"date":87,"type":67},"2031-03-01",{"name":5,"class":6},1]